Ha H et al. |
Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. |
2003 |
J. Biol. Chem. |
pmid:12637570
|
Ritchlin CT et al. |
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. |
2003 |
J. Clin. Invest. |
pmid:12639988
|
Takahashi E et al. |
High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. |
2002 |
J. Med. Dent. Sci. |
pmid:12641381
|
Fox SW et al. |
The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. |
2003 |
J. Immunol. |
pmid:12646633
|
Varsani H et al. |
Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). |
2003 |
Rheumatology (Oxford) |
pmid:12649407
|
Wise GE et al. |
Regulation of osteoprotegerin gene expression in dental follicle cells. |
2003 |
J. Dent. Res. |
pmid:12651935
|
Schoppet M et al. |
Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. |
2003 |
Circulation |
pmid:12654623
|
Nakano M et al. |
Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. |
2003 |
Oral Dis |
pmid:12657033
|
Ra JS et al. |
Osteoprotegerin inhibits proliferation of myeloid progenitor cells. |
2003 |
J. Hematother. Stem Cell Res. |
pmid:12662434
|
Szalay F et al. |
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. |
2003 |
J. Hepatol. |
pmid:12663228
|
Okada Y et al. |
Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. |
2003 |
J. Biol. Chem. |
pmid:12665515
|
Johnson-Pais TL et al. |
Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. |
2003 |
Int. J. Cancer |
pmid:12673693
|
Zaidi M et al. |
Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. |
2003 |
J. Bone Miner. Res. |
pmid:12674320
|
Terpos E et al. |
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. |
2003 |
Blood |
pmid:12689925
|
Zheng B et al. |
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. |
2003 |
Blood |
pmid:12689928
|
Moreno JL et al. |
IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. |
2003 |
Blood |
pmid:12689929
|
Dovio A et al. |
Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. |
2003 |
J. Endocrinol. |
pmid:12697042
|
Bell NH |
RANK ligand and the regulation of skeletal remodeling. |
2003 |
J. Clin. Invest. |
pmid:12697730
|
Eghbali-Fatourechi G et al. |
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. |
2003 |
J. Clin. Invest. |
pmid:12697741
|
Enomoto H et al. |
Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. |
2003 |
J. Biol. Chem. |
pmid:12697767
|
Nakashima T et al. |
RANKL and RANK as novel therapeutic targets for arthritis. |
2003 |
Curr Opin Rheumatol |
pmid:12707582
|
Al-Qawasmi RA et al. |
Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. |
2003 |
J. Dent. Res. |
pmid:12709501
|
Fujita D et al. |
Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. |
2003 |
Prostaglandins Leukot. Essent. Fatty Acids |
pmid:12711253
|
Tanaka S et al. |
Signal transduction pathways regulating osteoclast differentiation and function. |
2003 |
J. Bone Miner. Metab. |
pmid:12720046
|
Valleala H et al. |
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. |
2003 |
Eur. J. Endocrinol. |
pmid:12720535
|
Yonou H et al. |
Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. |
2003 |
Cancer Res. |
pmid:12727825
|
Capparelli C et al. |
Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. |
2003 |
J. Bone Miner. Res. |
pmid:12733724
|
Wong T et al. |
Therapeutic implications for interferon-alpha in arthritis: a pilot study. |
2003 |
J. Rheumatol. |
pmid:12734885
|
Lee ZH and Kim HH |
Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. |
2003 |
Biochem. Biophys. Res. Commun. |
pmid:12745060
|
Boyle WJ et al. |
Osteoclast differentiation and activation. |
2003 |
Nature |
pmid:12748652
|
Kanatani M et al. |
Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. |
2003 |
J. Cell. Physiol. |
pmid:12767054
|
Cheung J et al. |
Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. |
2003 |
J. Endocrinol. |
pmid:12773123
|
Nimmanapalli R and Bhalla K |
Targets in apoptosis signaling: promise of selective anticancer therapy. |
2003 |
Methods Mol. Biol. |
pmid:12777745
|
Garber K |
Why it hurts: researchers seek mechanisms of cancer pain. |
2003 |
J. Natl. Cancer Inst. |
pmid:12783923
|
Liu B et al. |
Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. |
2003 |
J. Oral Pathol. Med. |
pmid:12787044
|
Walsh MC and Choi Y |
Biology of the TRANCE axis. |
2003 Jun-Aug |
Cytokine Growth Factor Rev. |
pmid:12787563
|
Eaton CL and Coleman RE |
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. |
2003 |
Cancer Treat. Rev. |
pmid:12787713
|
Fahrleitner-Pammer A et al. |
Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. |
2003 |
Wien. Klin. Wochenschr. |
pmid:12793029
|
Dovio A et al. |
Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. |
2003 |
Clin. Cancer Res. |
pmid:12796409
|
Flick LM et al. |
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. |
2003 |
J. Orthop. Res. |
pmid:12798068
|
Kido S et al. |
Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. |
2003 |
Bone |
pmid:12810169
|
Kudlacek S et al. |
Serum levels of osteoprotegerin increase with age in a healthy adult population. |
2003 |
Bone |
pmid:12810175
|
Khapli SM et al. |
IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. |
2003 |
J. Immunol. |
pmid:12816992
|
Kawase Y et al. |
Bone malformations in interleukin-18 transgenic mice. |
2003 |
J. Bone Miner. Res. |
pmid:12817749
|
Kikuchi T et al. |
Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. |
2003 |
J. Dent. Res. |
pmid:12821717
|
D'Elia HF et al. |
Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. |
2003 |
Arthritis Res. Ther. |
pmid:12823855
|
Knudsen ST et al. |
Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. |
2003 |
Eur. J. Endocrinol. |
pmid:12824864
|
Ikeda T et al. |
Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. |
2003 |
Pathol. Int. |
pmid:12828610
|
Crotti T et al. |
Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. |
2003 |
J. Periodont. Res. |
pmid:12828654
|
Tazoe M et al. |
Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. |
2003 |
Arch. Oral Biol. |
pmid:12828991
|
Ito R et al. |
Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. |
2003 |
Virchows Arch. |
pmid:12838418
|
Terpos E et al. |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. |
2003 |
Int. J. Cancer |
pmid:12845688
|
Schett G et al. |
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. |
2003 |
Arthritis Rheum. |
pmid:12847699
|
Fizazi K et al. |
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. |
2003 |
Clin. Cancer Res. |
pmid:12855635
|
Okuma K et al. |
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. |
2003 |
J. Virol. |
pmid:12857926
|
Cheng X et al. |
The TNF receptor superfamily: role in immune inflammation and bone formation. |
2003 |
Immunol. Res. |
pmid:12857975
|
Shin MM et al. |
High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. |
2003 |
Exp. Mol. Med. |
pmid:12858015
|
Glossop JR et al. |
No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. |
2003 |
J. Rheumatol. |
pmid:12858434
|
Chen X et al. |
Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. |
2003 |
J. Nutr. Biochem. |
pmid:12873716
|
Bridgham JT and Johnson AL |
Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. |
2003 |
Biochem. Biophys. Res. Commun. |
pmid:12878204
|
Riggs BL et al. |
Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. |
2003 |
Osteoporos Int |
pmid:12879223
|
Sasaki T |
Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. |
2003 |
Microsc. Res. Tech. |
pmid:12879416
|
Helfrich MH |
Osteoclast diseases. |
2003 |
Microsc. Res. Tech. |
pmid:12879419
|
Younes A and Aggarwall BB |
Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. |
2003 |
Cancer |
pmid:12879461
|
Fukushima H et al. |
Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. |
2003 |
Eur. J. Oral Sci. |
pmid:12887401
|
Min JK et al. |
Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. |
2003 |
J. Biol. Chem. |
pmid:12893832
|
Teitelbaum SL and Ross FP |
Genetic regulation of osteoclast development and function. |
2003 |
Nat. Rev. Genet. |
pmid:12897775
|
Si AI et al. |
Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. |
2003 |
J. Cell. Biochem. |
pmid:12898514
|
Nitta K et al. |
The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. |
2003 |
Am. J. Kidney Dis. |
pmid:12900812
|
Hampson G et al. |
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. |
2003 |
Osteoporos Int |
pmid:12904840
|
Misra M et al. |
Serum osteoprotegerin in adolescent girls with anorexia nervosa. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915674
|
Lonergan M et al. |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915677
|
Kapczuk K et al. |
[Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. |
2003 |
Ginekol. Pol. |
pmid:12916277
|
Liu JZ et al. |
[Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. |
2003 |
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi |
pmid:12916296
|
Bendre MS et al. |
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. |
2003 |
Bone |
pmid:12919697
|
Tabb MM et al. |
Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. |
2003 |
J. Biol. Chem. |
pmid:12920130
|
Park HR et al. |
Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. |
2003 |
J. Korean Med. Sci. |
pmid:12923331
|
Paloneva J et al. |
DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. |
2003 |
J. Exp. Med. |
pmid:12925681
|
Nawroth P et al. |
[Osteoporosis and cardiovascular disease--two sides of the same coin?]. |
2003 |
Med. Klin. (Munich) |
pmid:12928809
|
Nakatsuka K et al. |
Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. |
2003 |
J. Bone Miner. Res. |
pmid:12929927
|
Li JP and Ling JQ |
[Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. |
2003 |
Zhonghua Kou Qiang Yi Xue Za Zhi |
pmid:12930661
|
Schett G et al. |
The role of osteoprotegerin in arthritis. |
2003 |
Arthritis Res. Ther. |
pmid:12932284
|
Karsdal MA et al. |
Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. |
2003 |
J. Biol. Chem. |
pmid:12933809
|
Benevolenskaia LI |
[Issues of osteoporosis in present-day medicine]. |
2003 |
Vestn. Akad. Med. Nauk SSSR |
pmid:12934464
|
Sugatani T et al. |
Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. |
2003 |
J. Cell. Biochem. |
pmid:12938156
|
Yamagami H et al. |
Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. |
2003 |
Biochem. Pharmacol. |
pmid:12948861
|
Srivastava S et al. |
Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. |
2003 |
J. Biol. Chem. |
pmid:12952963
|
Lee HA et al. |
Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. |
2003 |
Exp. Physiol. |
pmid:12955156
|
Yorke R et al. |
Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. |
2003 |
Eur. J. Cancer |
pmid:12957466
|
Zhang L et al. |
The role of calmodulin in the regulation of osteoclastogenesis. |
2003 |
Endocrinology |
pmid:12960067
|
Nakamura H et al. |
Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. |
2003 |
J. Med. Dent. Sci. |
pmid:12968638
|
Viereck V et al. |
Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12970288
|
Kaneyama K et al. |
Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. |
2003 |
Oral Surg Oral Med Oral Pathol Oral Radiol Endod |
pmid:12973279
|
Sakurai A et al. |
Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. |
2003 |
Infect. Immun. |
pmid:14500523
|
Kim HH et al. |
RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. |
2003 |
FASEB J. |
pmid:14500543
|
Nakamura M et al. |
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. |
2003 |
Endocrinology |
pmid:14500574
|
Zhang Z et al. |
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. |
2003 |
J. Immunol. |
pmid:14500659
|
Naumann U et al. |
Expression and functional activity of osteoprotegerin in human malignant gliomas. |
2004 |
Acta Neuropathol. |
pmid:14504888
|
Ueno Y et al. |
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. |
2003 |
J. Cell. Biochem. |
pmid:14505343
|
Kaneyama K et al. |
Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. |
2003 |
Int J Oral Maxillofac Surg |
pmid:14505625
|